What does a research label mean?

A research label does not settle the question.

BPC-157, ipamorelin, retatrutide and cagrilintide are ingredient names, not brands of approved medicines.

FDA discusses retatrutide and cagrilintide as unapproved weight-care drugs.

You do not need to know these names to look for care. If an offer names one, write it down and ask what health problem the seller claims it treats. The checks below do not prove those promises.

As of September 26, 2026, FDA records contain no approved United States product for BPC-157, ipamorelin or retatrutide. A

FDA is the Food and Drug Administration. A lack of approval alone cannot settle whether a pharmacy may prepare a medicine to order.

Compounding is the name for preparing medicine to order. Its rules are a separate part of the check.

Federal law, according to FDA as of September 26, 2026, bars using retatrutide or cagrilintide to prepare medicine to order. C

BPC-157 and ipamorelin have separate records. FDA still lists safety concerns beside withdrawn requests to allow them. Ipamorelin appears there as ipamorelin acetate, a form of that ingredient. Withdrawal did not grant permission to use them. D

For BPC-157, FDA’s July 2026 documents show no applicable ingredient quality standard, no use in an approved drug and no place on the official ingredient list. It therefore fails the ingredient tests for ordinary pharmacy compounding.

Ask the pharmacy which ingredient rule it relies on for ipamorelin. Check its answer against FDA’s ingredient records; a prescription alone does not answer this.

Washington has addressed research ingredients.

As of September 30, 2026, Washington’s Pharmacy Commission says patient medicines cannot be compounded from ingredients labelled for research or against human use. B

The Commission’s July 31, 2026 notice to pharmacies explains rules already in place. It does not create a new law approving or banning named peptides.

Ask the clinician or pharmacy to explain the exact product and the rules being relied on.

Check what the seller promises in the advert.

In warning letters checked September 26, 2026, FDA looked at sellers’ promises to treat health problems. It said those promises showed the products were meant as medicines for people, despite research-only labels. E

These letters set out FDA’s claims about particular businesses. They are not court decisions.

FDA also cautions that research-labelled products sold straight to people for use may be harmful and have unknown quality. C

Before agreeing, ask who will assess you, who writes the prescription and which pharmacy supplies the medicine. Check their licences and ask the pharmacy which rules allow it to prepare that exact medicine.